Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vadastuximab talirine in newly diagnosed AML (CASCADE)
NCT02785900Phase 3Terminated
- Sponsor
- Seagen Inc.
- Start
- May 2016
- Primary completion
- Oct 2017
- Modality
- Recombinant Proteins and Enzymes, Antibody-Drug Conjugates (ADCs), Monoclonal Antibodies
- Countries
- 16
01
Overview
Phase 3, randomised, double-blind trial in acute myeloid leukemia (AML) comparing Vadastuximab Talirine + HMA with Placebo + HMA (2 arms). Primary endpoints: Overall Survival at 1.5 years and Composite Complete Remission Rate at 1.5 years. Started May 2016; status: terminated.
02
Drugs
vadastuximab talirine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT02785900.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02785900.